222. Primary nephrotic syndrome Clinical trials / Disease details


Clinical trials : 310 Drugs : 295 - (DrugBank : 117) / Drug target genes : 63 - Drug target pathways : 194

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05441826
(ClinicalTrials.gov)
May 3, 20227/6/2022Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)A Phase 2 Study of VB119 in Adult Subjects With Steroid-Sensitive Primary Minimal Change Disease (MCD) or Primary Focal Segmental Glomerulosclerosis (FSGS)Minimal Change Disease;Focal Segmental GlomerulosclerosisDrug: VB119ValenzaBio, Inc.NULLActive, not recruiting18 YearsN/AAll20Phase 2United States
2NCT04652570
(ClinicalTrials.gov)
May 5, 202123/11/2020Efficacy and Safety of VB119 in Subjects With Membranous NephropathyA Phase 1b/2a Study of VB119 in Adult Subjects With Primary Membranous NephropathyMembranous NephropathyDrug: VB119ValenzaBio, Inc.NULLRecruiting18 YearsN/AAll30Phase 1/Phase 2United States;Mexico;United Kingdom